Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing
Mirus Bio's transfection reagents strengthen Merck's upstream portfolio Acquisition will advance Merck's ambition to provide a fully integrated and comprehensive solution for viral vector
Source: finanznachrichten.de